116 related articles for article (PubMed ID: 12824910)
1. An efficient method to prepare T cell receptor gene-transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell-therapy.
Tsuji T; Chamoto K; Funamoto H; Kosaka A; Matsuzaki J; Abe H; Fujio K; Yamamoto K; Kitamura T; Togashi Y; Koda T; Nishimura T
Cancer Sci; 2003 Apr; 94(4):389-93. PubMed ID: 12824910
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.
Tahara H; Fujio K; Araki Y; Setoguchi K; Misaki Y; Kitamura T; Yamamoto K
J Immunol; 2003 Aug; 171(4):2154-60. PubMed ID: 12902522
[TBL] [Abstract][Full Text] [Related]
3. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
6. TCR alpha beta+ anti-tumor cytolytic T lymphocytes express NKR-P1 whilethe anti-tumor activity of TCR gamma delta+ T lymphocytes is not correlated to NKR-P1 expression.
Yrlid U; Petersson E; Dohlsten M; Hedlund G
Cell Immunol; 1996 Nov; 173(2):287-94. PubMed ID: 8912889
[TBL] [Abstract][Full Text] [Related]
7. CD8+ tumor-specific Tc cells primed in vivo or in vitro against the BALB/c plasmacytoma ADJ-PC-5 use the same TcR V beta families but display distinct TC1 or TC2 characteristics.
Becker C; Kölsch E; Pauels HG
Immunobiology; 1997 Jun; 197(1):16-30. PubMed ID: 9241528
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of P1A35-43/beta2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model.
Zhang X; Mei W; Zhang L; Yu H; Zhao X; Fan X; Qian G; Ge S
Oncol Rep; 2009 Nov; 22(5):1213-20. PubMed ID: 19787242
[TBL] [Abstract][Full Text] [Related]
9. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
[TBL] [Abstract][Full Text] [Related]
10. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Clay TM; Custer MC; Spiess PJ; Nishimura MI
Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
[TBL] [Abstract][Full Text] [Related]
13. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
[TBL] [Abstract][Full Text] [Related]
14. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
[TBL] [Abstract][Full Text] [Related]
15. Characterization of B16 melanoma-specific cytotoxic T lymphocytes.
Harada M; Tamada K; Abe K; Li T; Onoe Y; Tada H; Tatsugami K; Ando T; Kimura G; Nomoto K
Cancer Immunol Immunother; 1998 Dec; 47(4):198-204. PubMed ID: 9875672
[TBL] [Abstract][Full Text] [Related]
16. Retroviral-mediated expression of an MHC class I-restricted T cell receptor in the CD8 T cell compartment of bone marrow-reconstituted mice.
Pogulis RJ; Hansen MJ; Pease LR
Hum Gene Ther; 1998 Oct; 9(15):2285-97. PubMed ID: 9794212
[TBL] [Abstract][Full Text] [Related]
17. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation.
Thomas MJ; Noble A; Sawicka E; Askenase PW; Kemeny DM
J Immunol; 2002 Jan; 168(1):216-23. PubMed ID: 11751965
[TBL] [Abstract][Full Text] [Related]
18. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
19. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
